Profitability
This table compares Vectura Group and ProMetic Life Sciences’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Vectura Group | N/A | N/A | N/A |
ProMetic Life Sciences | -894.02% | -3,350.55% | -67.76% |
Risk and Volatility
Vectura Group has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, ProMetic Life Sciences has a beta of 2.46, meaning that its share price is 146% more volatile than the S&P 500.
Valuation and Earnings
This table compares Vectura Group and ProMetic Life Sciences”s revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Vectura Group | $244.76 million | 4.37 | $157.16 million | $0.26 | 6.81 |
ProMetic Life Sciences | $36.55 million | 3.49 | -$150.73 million | N/A | N/A |
Vectura Group has higher revenue and earnings than ProMetic Life Sciences.
Insider and Institutional Ownership
0.1% of ProMetic Life Sciences shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Vectura Group beats ProMetic Life Sciences on 6 of the 8 factors compared between the two stocks.
About Vectura Group
Vectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom.
About ProMetic Life Sciences
Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.